Theriva Biologics, Inc. (TOVX)
NYSEAMERICAN: TOVX · IEX Real-Time Price · USD
0.270
+0.008 (3.05%)
Jul 22, 2024, 10:07 AM EDT - Market open
Theriva Biologics Employees
Theriva Biologics had 22 employees as of December 31, 2023. The number of employees increased by 1 or 4.76% compared to the previous year.
Employees
22
Change (1Y)
1
Growth (1Y)
4.76%
Revenue / Employee
n/a
Profits / Employee
-$865,318
Market Cap
4.60M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
Genetic Technologies | 60 |
Sharps Technology | 57 |
Intelligent Bio Solutions | 51 |
Predictive Oncology | 35 |
Processa Pharmaceuticals | 13 |
Sonnet BioTherapeutics Holdings | 12 |
CERo Therapeutics Holdings | 9 |
Adial Pharmaceuticals | 7 |
TOVX News
- 2 months ago - Theriva™ Biologics Announces Fast Track Designation Granted by the U.S. FDA for VCN-01 for the Treatment of Metastatic Pancreatic Cancer - GlobeNewsWire
- 2 months ago - Theriva™ Biologics to Participate in the A.G.P. Virtual Healthcare Conference - GlobeNewsWire
- 2 months ago - Theriva™ Biologics Reports First Quarter 2024 Operational Highlights and Financial Results - GlobeNewsWire
- 3 months ago - Theriva™ Biologics to Discuss the Trial Design for VIRAGE - a Phase 2b Clinical Study of Systemically Administered VCN-01 in Combination with Chemotherapy in Pancreatic Ductal Adenocarcinoma - at the 2024 American Society of Clinical Oncology (ASCO) Annua - GlobeNewsWire
- 3 months ago - Theriva™ Biologics Announces Positive Topline Data from Investigator Sponsored Phase 1 Trial of Intravitreal VCN-01 in Pediatric Patients with Refractory Retinoblastoma - GlobeNewsWire
- 3 months ago - Theriva™ Biologics to Present Preclinical Data Supporting the Potential Synergy of VCN-01 and First-Line Pancreatic Cancer Chemotherapy Regimens at the American Society for Cell and Gene Therapy 27th Annual Meeting - GlobeNewsWire
- 3 months ago - Theriva™ Biologics Announces Presentation at the American Society for Cell and Gene Therapy 27th Annual Meeting - GlobeNewsWire
- 4 months ago - Theriva™ Biologics Reports Full-Year 2023 Operational Highlights and Financial Results - GlobeNewsWire